| Hydrogen sulfide promotes wheat seed germination and alleviates oxidative damage against copper stress H Zhang, LY Hu, KD Hu, YD He, SH Wang, JP Luo Journal of integrative plant biology 50 (12), 1518-1529, 2008 | 455 | 2008 |
| Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation P Zhang, D Wang, Y Zhao, S Ren, K Gao, Z Ye, S Wang, CW Pan, Y Zhu, ... Nature medicine 23 (9), 1055-1062, 2017 | 275 | 2017 |
| Targeting signaling pathways in prostate cancer: mechanisms and clinical trials Y He, W Xu, YT Xiao, H Huang, D Gu, S Ren Signal transduction and targeted therapy 7 (1), 198, 2022 | 132 | 2022 |
| Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer Y He, J Lu, Z Ye, S Hao, L Wang, M Kohli, DJ Tindall, B Li, R Zhu, L Wang, ... Nucleic acids research 46 (4), 1895-1911, 2018 | 104 | 2018 |
| Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer Y He, S Peng, J Wang, H Chen, X Cong, A Chen, M Hu, M Qin, H Wu, ... Nature communications 7 (1), 13122, 2016 | 93 | 2016 |
| Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer M Hu, S Peng, Y He, M Qin, X Cong, Y Xing, M Liu, Z Yi Oncotarget 6 (17), 15348, 2015 | 93 | 2015 |
| Destruction of DNA‐binding proteins by programmable oligonucleotide PROTAC (O'PROTAC): effective targeting of LEF1 and ERG J Shao, Y Yan, D Ding, D Wang, Y He, Y Pan, W Yan, A Kharbanda, H Li, ... Advanced Science 8 (20), 2102555, 2021 | 89 | 2021 |
| A noncanonical AR addiction drives enzalutamide resistance in prostate cancer Y He, T Wei, Z Ye, JJ Orme, D Lin, H Sheng, L Fazli, R Jeffrey Karnes, ... Nature communications 12 (1), 1521, 2021 | 79 | 2021 |
| EZH 2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis Y Zhao, L Ding, D Wang, Z Ye, Y He, L Ma, R Zhu, Y Pan, Q Wu, K Pang, ... The EMBO journal 38 (5), e99599, 2019 | 75 | 2019 |
| FOXA1 overexpression suppresses interferon signaling and immune response in cancer Y He, L Wang, T Wei, YT Xiao, H Sheng, H Su, DP Hollern, X Zhang, J Ma, ... The Journal of clinical investigation 131 (14), 2021 | 69 | 2021 |
| TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer AM Blee, Y He, Y Yang, Z Ye, Y Yan, Y Pan, T Ma, J Dugdale, E Kuehn, ... Clinical Cancer Research 24 (18), 4551-4565, 2018 | 65 | 2018 |
| Loss of FOXO1 cooperates with TMPRSS2–ERG overexpression to promote prostate tumorigenesis and cell invasion Y Yang, AM Blee, D Wang, J An, Y Pan, Y Yan, T Ma, Y He, J Dugdale, ... Cancer research 77 (23), 6524-6537, 2017 | 65 | 2017 |
| PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer Y Yang, Y Bai, Y He, Y Zhao, J Chen, L Ma, Y Pan, M Hinten, J Zhang, ... Clinical Cancer Research 24 (4), 834-846, 2018 | 63 | 2018 |
| Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer Y Yan, J An, Y Yang, D Wu, Y Bai, W Cao, L Ma, J Chen, Z Yu, Y He, X Jin, ... EMBO molecular medicine 10 (4), e8478, 2018 | 58 | 2018 |
| Inhibition of EZH2 by chemo-and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer C Wu, X Jin, J Yang, Y Yang, Y He, L Ding, Y Pan, S Chen, J Jiang, ... Oncotarget 7 (3), 3440, 2015 | 56 | 2015 |
| Targeting pyruvate carboxylase by a small molecule suppresses breast cancer progression Q Lin, Y He, X Wang, Y Zhang, M Hu, W Guo, Y He, T Zhang, L Lai, Z Sun, ... Advanced Science 7 (9), 1903483, 2020 | 53 | 2020 |
| A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer J Wang, Y Xing, Y Wang, Y He, L Wang, S Peng, L Yang, J Xie, X Li, ... Journal of Experimental & Clinical Cancer Research 38, 1-14, 2019 | 42 | 2019 |
| Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside X Bao, Y Liang, H Chang, T Cai, B Feng, K Gordon, Y Zhu, H Shi, Y He, ... Signal Transduction and Targeted Therapy 9 (1), 13, 2024 | 41 | 2024 |
| Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer S Wen, Y He, L Wang, J Zhang, C Quan, Y Niu, H Huang Oncogene 39 (42), 6556-6571, 2020 | 38 | 2020 |
| Mutated SPOP E3 ligase promotes 17βHSD4 protein degradation to drive androgenesis and prostate cancer progression L Shi, Y Yan, Y He, B Yan, Y Pan, JJ Orme, J Zhang, W Xu, J Pang, ... Cancer research 81 (13), 3593-3606, 2021 | 24 | 2021 |
